Опыт использования линезолида при лечении хирургической инфекции кожи и мягких тканей у ВИЧ-инфицированных
Опыт использования линезолида при лечении хирургической инфекции кожи и мягких тканей у ВИЧ-инфицированных
Хачатрян Н.Н., Дизенков И.М., Смирнов Г.Г., Булискерия Т.Н. Опыт использования линезолида при лечении хирургической инфекции кожи и мягких тканей у ВИЧ-инфицированных. Consilium Medicum. 2008; 10 (1): 49–53.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Список литературы
1. Gluck T. Linezolid vs Vancomycin for Soft-Tissue Infections. J Watch Infect Dis 2005; 8.
2. Zhiming Li, Wilke RJ, Rittenhouse BE et al. Lenth of stay with Linezolid versus Vancomycin for MRS. Infect Pharmacother 2001; 21(3): 263–74.
3. Iyer S.Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Academ Dermatol 2004; 50 (6): 854–8.
4. Fagan SP, Berger DH, Rahwan K, Awad SS. Spider bites presenting with methicillin-resistant Staphylococcus aureus soft tissue infection require early aggressive treatment. Surgical Infect 2003; 4 (4): 311–5.
5. Chang FY, MacDonald BB, Peacock JE et al. A prospective multicentre studies of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine 2003; 82 (5): 322–32.
6. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus-an emerging problem for the management of skin and soft tissue infections (review). Cur Opinion Infect Dis 2003; 16 (2): 103–24.
7. Wilke RJ, Glick HA, Li JZ, Rittenhouse BE. Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. Intern J Technol Assessment Health Care 2002; 18 (3): 540–54.
8. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34 (11): 1481–90.
9. Li JZ, Willke RJ, Rittenhouse BE. Glick HA Approaches to analysis of length of hospital stay relayed to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. Pharmacotherapy 2002; 22 (2Pt2): 45S–54S.
10. Kowalik M, Ellert-Zygadlowska J, Smiatacz T et al. Staphylococcus aureua sepsis-still life threatening disease. Polski Merkuriusz Lekarski 2001; 11 (64): 352–6.
11. Gospell IB, Mercer JL, Neville SA еt al. Non-multiresistant and multiresistant methicillin-resistant Staphylococcus aureus in community-acquired infections. Med J Australia 2001; 174 (12): 627–30.
12. Li Z, Willke RJ, Pinto LA et al Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001; 21 (3): 263–74.
13. Lacy MK, Tessier PR, Nicolau DP et al. Comparison of vancomycin pharmacodynamics (1g every 12 or 24 h) against methicillin-resistant staphylococci. Internat J Antimicrob Agents 2000; 15 (1): 25030.
14. Iwahara T, Ichiyama S, Nada T et al. Clinical and epidemiologic investigations of nosocomial pulmonary infections caused by methicillin-resistant Staphylococcus aureus. Chest 1994; 105 (3): 826–31.
15. Manfredi R, CalzaL, Chiodo F. Epidemiology and microbiology of cellulitis and bacterial soft tissue infection during HIV disease: a 10 year survey. J Cutan Pathol 2002; 29 (3): 168–72.
16. Popov AV, Cherkasov VA, Palatova LF, Zverev SY. Pyoinflammatory processes in soft tissues among HIV-positive injecting drug users co-infected with hepatitis B and C viruses. 9th European AIDS conference 2003 October, Poland.
17. Weigelt J, Itani K, Stevens D et al. Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections. Antimicrobial Agents and Chemotherapy. 2005; 49 (6): 2260–6.
18. Stevens DL, Smith LG, Bruss JB et al. Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections. Antimicrob Agents Chemother 2000; 44 (12): 3408–13.
19. Яковлев С.В., Проценко Д.Н. Линезолид: новые возможности терапии инфекций, вызванных полирезистентными грамположительными микроорганизмами. 2001.
20. Boyce JM, Havill NL et al. Do Infection Control Measures Work for Methicillin-Resistant Staphylococcus aureus? Infect Control Hospital Epidemiol 2004; 25 (5): 395–401.
21. Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs Vancomycin Analysis of two Double-Blind Studies of Patients With Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia. Chest November 2003; 123: 1789–97.
22. Смирнов Г.Г., Булискерия Т.Н., Хачатрян Н.Н. Хирургическая помощь ВИЧ-инфицированным больным. Хирургия. 2000; 7: 46–9.
23. Покровский В.В., Ладная Н.Н., Голиусов А.Т. Развитие эпидемии ВИЧ-инфекции в России. Эпидемиология и инфекционные болезни. 2001; 1: 10.
24. Кравченко А.В. Клинико-патогенетические особенности нарушений системы гомеостаза у больных ВИЧ-инфекцией. Центральный научно-исследовательский институт эпидемиологии МЗ РФ. М., 1999.
25. Покровский В.В. ВИЧ-инфекция. Клиника, диагностика и лечение. М.: Медицина, 2000.
26. Белобородов В.Б. Сепсис, вызванный грамположительными бактериями: современное значение гликопептидных антибиотиков. Инфекции и антимикробная терапия. 2001;3 (3): 77–81.
27. Stevens DL, Herr D, Lampiris H et al. Linezolid versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections. Clin Infect Dis, 2002; 34: 1481–90.
28. Ильина Н.И., Латышева Т.В., Пинегина Б.В. Синдром вторичной иммунной недостаточности. Иммунология. 2000; 5: 8–9.
29. Bartlett JG. Medical Management of HIV Infection. Baltimore: J Hopkins University School of Medicine, 1998.
30. Wastell C, Cerless D, Keeling N. Surgery and human immunodeficiency virus – 1 infection. Am J Surg 1996; 172: 89–92.
31. UNAIDS/WHO AIDS Epidemic Update. Geneva, 1999; 172: 89–92.
32. Sandre MA, Voldenberg A. The Clinical Management of AIDS. Philadelphia, 1997.
33. Bartlett JG. DHHS guidelines: the most recent revisions. The Hopkins HIV report. 1998; 10: 1-9.
34. Ho DD. Dynamics of HIV replication in vivo. S Clin Invest 1997; 99: 2565–7.
35. Диагностика и лечение ВИЧ-инфекции. Методические указания для врачей. Под ред. В.В.Покровского. М., 1999.
2. Zhiming Li, Wilke RJ, Rittenhouse BE et al. Lenth of stay with Linezolid versus Vancomycin for MRS. Infect Pharmacother 2001; 21(3): 263–74.
3. Iyer S.Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Academ Dermatol 2004; 50 (6): 854–8.
4. Fagan SP, Berger DH, Rahwan K, Awad SS. Spider bites presenting with methicillin-resistant Staphylococcus aureus soft tissue infection require early aggressive treatment. Surgical Infect 2003; 4 (4): 311–5.
5. Chang FY, MacDonald BB, Peacock JE et al. A prospective multicentre studies of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine 2003; 82 (5): 322–32.
6. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus-an emerging problem for the management of skin and soft tissue infections (review). Cur Opinion Infect Dis 2003; 16 (2): 103–24.
7. Wilke RJ, Glick HA, Li JZ, Rittenhouse BE. Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. Intern J Technol Assessment Health Care 2002; 18 (3): 540–54.
8. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34 (11): 1481–90.
9. Li JZ, Willke RJ, Rittenhouse BE. Glick HA Approaches to analysis of length of hospital stay relayed to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. Pharmacotherapy 2002; 22 (2Pt2): 45S–54S.
10. Kowalik M, Ellert-Zygadlowska J, Smiatacz T et al. Staphylococcus aureua sepsis-still life threatening disease. Polski Merkuriusz Lekarski 2001; 11 (64): 352–6.
11. Gospell IB, Mercer JL, Neville SA еt al. Non-multiresistant and multiresistant methicillin-resistant Staphylococcus aureus in community-acquired infections. Med J Australia 2001; 174 (12): 627–30.
12. Li Z, Willke RJ, Pinto LA et al Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001; 21 (3): 263–74.
13. Lacy MK, Tessier PR, Nicolau DP et al. Comparison of vancomycin pharmacodynamics (1g every 12 or 24 h) against methicillin-resistant staphylococci. Internat J Antimicrob Agents 2000; 15 (1): 25030.
14. Iwahara T, Ichiyama S, Nada T et al. Clinical and epidemiologic investigations of nosocomial pulmonary infections caused by methicillin-resistant Staphylococcus aureus. Chest 1994; 105 (3): 826–31.
15. Manfredi R, CalzaL, Chiodo F. Epidemiology and microbiology of cellulitis and bacterial soft tissue infection during HIV disease: a 10 year survey. J Cutan Pathol 2002; 29 (3): 168–72.
16. Popov AV, Cherkasov VA, Palatova LF, Zverev SY. Pyoinflammatory processes in soft tissues among HIV-positive injecting drug users co-infected with hepatitis B and C viruses. 9th European AIDS conference 2003 October, Poland.
17. Weigelt J, Itani K, Stevens D et al. Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections. Antimicrobial Agents and Chemotherapy. 2005; 49 (6): 2260–6.
18. Stevens DL, Smith LG, Bruss JB et al. Randomized Comparison of Linezolid (PNU-100766) versus Oxacillin-Dicloxacillin for Treatment of Complicated Skin and Soft Tissue Infections. Antimicrob Agents Chemother 2000; 44 (12): 3408–13.
19. Яковлев С.В., Проценко Д.Н. Линезолид: новые возможности терапии инфекций, вызванных полирезистентными грамположительными микроорганизмами. 2001.
20. Boyce JM, Havill NL et al. Do Infection Control Measures Work for Methicillin-Resistant Staphylococcus aureus? Infect Control Hospital Epidemiol 2004; 25 (5): 395–401.
21. Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs Vancomycin Analysis of two Double-Blind Studies of Patients With Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia. Chest November 2003; 123: 1789–97.
22. Смирнов Г.Г., Булискерия Т.Н., Хачатрян Н.Н. Хирургическая помощь ВИЧ-инфицированным больным. Хирургия. 2000; 7: 46–9.
23. Покровский В.В., Ладная Н.Н., Голиусов А.Т. Развитие эпидемии ВИЧ-инфекции в России. Эпидемиология и инфекционные болезни. 2001; 1: 10.
24. Кравченко А.В. Клинико-патогенетические особенности нарушений системы гомеостаза у больных ВИЧ-инфекцией. Центральный научно-исследовательский институт эпидемиологии МЗ РФ. М., 1999.
25. Покровский В.В. ВИЧ-инфекция. Клиника, диагностика и лечение. М.: Медицина, 2000.
26. Белобородов В.Б. Сепсис, вызванный грамположительными бактериями: современное значение гликопептидных антибиотиков. Инфекции и антимикробная терапия. 2001;3 (3): 77–81.
27. Stevens DL, Herr D, Lampiris H et al. Linezolid versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections. Clin Infect Dis, 2002; 34: 1481–90.
28. Ильина Н.И., Латышева Т.В., Пинегина Б.В. Синдром вторичной иммунной недостаточности. Иммунология. 2000; 5: 8–9.
29. Bartlett JG. Medical Management of HIV Infection. Baltimore: J Hopkins University School of Medicine, 1998.
30. Wastell C, Cerless D, Keeling N. Surgery and human immunodeficiency virus – 1 infection. Am J Surg 1996; 172: 89–92.
31. UNAIDS/WHO AIDS Epidemic Update. Geneva, 1999; 172: 89–92.
32. Sandre MA, Voldenberg A. The Clinical Management of AIDS. Philadelphia, 1997.
33. Bartlett JG. DHHS guidelines: the most recent revisions. The Hopkins HIV report. 1998; 10: 1-9.
34. Ho DD. Dynamics of HIV replication in vivo. S Clin Invest 1997; 99: 2565–7.
35. Диагностика и лечение ВИЧ-инфекции. Методические указания для врачей. Под ред. В.В.Покровского. М., 1999.
Авторы
Н.Н.Хачатрян, И.М.Дизенков, Г.Г.Смирнов, Т.Н.Булискерия
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.